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Summary 
 
This workshop represented the first international interdisciplinary meeting of experts 
and stakeholders in a process that is intended to culminate in the adoption of a stem 
cell or broader biosciences research governance scheme in Argentina.  It was attended 
by over 50 participants, including scientists and physicians, academics, and policy-
makers and advisors.  The emphasis of this workshop was to consider the United 
Kingdom experience in stem cell regulation, to explore options for an Argentine 
model, and to map future actions. 
 
Presentations 
 
On 29 November 2007, Dr. Lino Barañao, Director of the Agency for the Promotion 
and Science & Technology (now Minister of Science & Technology), welcomed the 
participants, followed by Fabiana Arzuaga, Argentine Stem Cell Commission and 
University of Buenos Aires. 
 
Professor Graeme Laurie, Director of SCRIPT, the AHRC Centre for Research on 
Intellectual Property and Technology Law, University of Edinburgh, indicated that the 
objective of the workshop was to identify key elements in stem cell regulation, and to 
explore options for establishing an optimal regulatory approach for Argentina.  As a 
preliminary step in the overall process, the workshop would address the state of art of 
the science, lessons from abroad, and the role of public engagement. 
 
Dr. Paul de Souza, CSO, Roslin Cells Ltd., and Senior Research Fellow, University of 
Edinburgh, outlined his background as a developmental biologist, and explained the 
mechanics and difficulties of deriving therapeutic grade human embryonic stem cells. 
 
Mr. Hugh Whittall, Director of the Nuffield Council of Bioethics, outlined the UK’s 
liberal and facilitative regime, and drew on his own experience of working with the 
Human Fertilisation and Embryology Authority (HFEA).  He highlighted the 
importance of consent to that regime, the role of the HFEA and Parliament in ongoing 
engagement with the science as it evolves, and the importance of the research 
purposes criteria to the operability of the UK regime.  After noting some of the 
problems with the UK regime (most notably its complexity and fragmentation, its 
numerous influences, and continued disagreement over core issues), he recommended 
that Argentina needs to talk, consult and engage, be flexible, and horizon-gaze, and 
thereby generally create a supportive environment for good science to flourish. 
 
  
Mr. Shawn Harmon, Research Fellow at InnoGen and SCRIPT, University of 
Edinburgh, reiterated the importance of engagement to regulatory creativity and 
public acceptance.  He also echoed the general value of an integrated governance 
approach with clear processes based on an explicit statement of guiding principles.  
He went on to outline his empirical research project, “Governing Emerging 
Technologies: Social Value and Stem Cell Regulation in Argentina” (ESRC Award 
No. RES-000-22-2678). 
 
Dr. Pablo Argibay, Hospital Italiano, noted that Argentina experienced 21,000 heart 
attaches per annum, a fact which made both preventative and post-event treatment 
very important for Argentine healthcare.  He highlighted the importance of the 
Instituto Argentino de Transplante de Organos Tejidos y Celulas (INCUCAI) to work 
in this area, but noted the many gaps in the governance of clinical conduct and trials, 
and the importance of the international context (including direction found in the EU 
Clinical Trials Directive).  He suggested that the level of evidence required for 
approval of stem cell therapies is an issue of key importance for researchers and 
clinicians, and one that is currently very unclear. 
 
Dr. Fernando Pitossi, Fleni Hospital, together with his research team, is conducting 
genetic manipulation to get better function from stem cells.  He spoke about his pride 
in working in this area, but noted the many uncertainties of the existing governance 
setting. 
 
Dr Armando Perichon, indicated that a total absence of research regulation in 
Argentina led to the rather quick establishment of INCUCAI, which regulates the 
transplantation of organs, tissue and cells into human patients.  Created in 2007 by 
Resolution, and with very little debate, he suggested that its remit was not broad 
enough, and that the separate and non-binding work of the ethics committee is a 
particular problem. 
 
Dr. Ana del Pozo, Banco de Sangre de Cordon Umbilical, outlined a recent cord 
blood banking initiative and attempts at its governance, drawing on the international 
and Spanish experiences. She emphasised that cord blood banks are a “public good” 
needing strong protection, particularly around standards, so that the common good 
could be promoted.  She recommended that regulation should be the same whether an 
organisation (in the cord blood banking or other biomedical settings) is private or 
public, and international standards should be drawn on. 
 
Dr. Inés Pertino, Argentine Ministry of Health, stated that many and diverse interests 
have to be addressed together with the political objective of promoting science, that 
national laws are probably the best way to proceed, but that formulating a regulatory 
framework is not easy.  The existing regime is full of holes, but work is progressing 
on Good Clinical Practice guidelines, accreditation for ethics committee membership, 
and provision of information (on consent, vulnerability, research and international 
standards) through the internet. 
 
Debates and Reports 
 
 
 On 30 November 2007, the participants divided into three groups which reported as 
follows: 
 
• Public Perception: Chaired S. Harmon, this group highlighted the 
importance of language (which can be an ethical issue) in encouraging debate 
around stem cell activities.  Whether addressing stem cell sourcing or 
research purposes, invested stakeholders need to talk to publics and build a 
culture of communication; this can only be done through the cooperation of 
universities, research centres, and academics/scientists.  This needs to start at 
the level of values and progress from there.  It was noted that power groups in 
society play an important part in handling/filtering knowledge and 
constructing truth, so invested stakeholders need to build their dialogues 
around the biological status of the subject matter, and must be careful to 
temper their promises concerning the deliverables (short and medium term in 
particular) of science.  It was noted that Argentina is probably hindered by its 
lack of sociological and philosophical work in this area (as compared to the 
UK which has a longer track record of involving the public in policy-making). 
 
 
• Regulation: Chaired by H. Whittall, this group explored the role and 
responsibilities of INCUCAI, which has a role in health delivery under the 
Ministry of Health.  However, it is not clear that it has authority over, and no 
one is sure what to do about, the lives of stem cells. This group emphasised 
the value of regulation, the importance of biological understandings 
informing the debate, and the absolute need for communication and 
understanding between institutions so that products and processes can travel 
along the innovation (and regulatory) pipeline with confidence.  It was 
determined that transparency should be a key guiding value, but that other 
social values need to be recognised and play a part in the discussion if public 
benefits are to be realised. 
 
• Science: Chaired by P. de Souza, this group identified the public-private 
divide and the research-therapy divide and emphasised that a new regime 
must be aware of the different (and overlapping) needs within each setting.  
Current Ministry of Health institutions (INCUCAI, which addresses 
transplantation, and ANMAT, which addresses ethics in public institutions) 
have divided and unclear responsibilities, and trajectories in science are 
causing greater confusion and potential for diffusion and tension.  The 
complexity and fragmentation is heightened by the existence of other relevant 
institutions, such as CONICET under the Ministry of Science.  Grey zones 
exist regarding authority over the all-important ethical oversight issues, 
including consent, coercion, standards, etc. (particularly as materials move 
through the system and from the remit of one institution to the next), the role 
of international standards, the position of private (as opposed to public) 
entities, and the role of publication.  It is currently clear that the regulatory 
regime should be blind to the public/private distinction, and that different but 
very clear standards must be articulated for research and therapy (and 
materials should not be able to jump from one stream to the next). 
 
 
 
  
 
Summation / Conclusions 
 
Dr. Lino Barañao thanked everyone for participating.  With respect to the messages 
that came out of the meeting, he thought that those relating to consultation were 
particularly important, for the future operation of both public and private entities in 
this field.  However, he exhibited caution, suggesting that public consultations 
conducted too early – before the right information or the right amount of information 
is yet available – could be damaging, particularly to larger, more established 
enterprises which are concerned about reputation.  Ultimately, he agreed that 
consultation can help to inform public information campaigns, and therefore public 
policy in this field. 
 
Next Steps 
 
The rapporteurs would work closely with attendees and others to produce policy 
biefings and reports on the meeting and to determine how matters should proceed 
from here. A further meeting would be held in 2008 to consider other experiences of 
regulation and reform, drawing in particular on the UK’s experience with the Human 
Tissue Authority and reforms due for the Human Fertilisation and Embryology 
Authority.  
